James C. Yao

38.6k citations

326 papers · 23.0k indexed · 7 hit papers · h-index 65

Impact in

Neurology top 0.02%
- Neuroblastoma Research and Treatments
Oncology top 0.02%
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research

Papers in

Neurology 135
- Neuroblastoma Research and Treatments 133
Oncology 213
- Lung Cancer Research Studies 154
- Pancreatic and Hepatic Oncology Research 32
- Colorectal Cancer Treatments and Studies 18

Co-authors: Alexandria T. Phan Asif Rashid Douglas B. Evans Manal M. Hassan Jaffer A. Ajani Colleen Leary Arvind Dasari Daniel M. Halperin
Journals: Journal of Clinical Oncology (97 papers)Pancreas (25 papers)Annals of Oncology (14 papers)Clinical Cancer Research (13 papers)Cancer (12 papers)
Partner nations: United States Switzerland France

In The Last Decade

James C. Yao

318 papers receiving 22.6k citations

Hit Papers

7 papers align trajectories log scale

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211) 2022 · 125 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Journal of Clinical Oncology
2017 JAMA Oncology
2013 Pancreas
2011 New England Journal of Medicine
2011 The Lancet
2009 Journal of Clinical Oncology
2008 Journal of Clinical Oncology

Peers

Countries citing papers authored by James C. Yao

Since Specialization

Citations

This map shows the geographic impact of James C. Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James C. Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James C. Yao more than expected).

Fields of papers citing papers by James C. Yao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James C. Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James C. Yao. The network helps show where James C. Yao may publish in the future.

Co-authors

The 25 scholars most cited alongside James C. Yao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James C. Yao Line = papers co-authored together James C. Yao links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal Clinical Cancer Research ·Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio I. Wistuba, 時彦田中, James C. Yao, 李向阳, Mark Knafl, Scott E. Woodman, Cathy Eng, Daniel M. Halperin	2025	1
2	Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study Cancers ·Matheus Sewastjanow‐Silva, Lianchun Xiao, Graciela M. Nogueras‐González, Xuemei Wang, Wayne L. Hofstetter, Stephen G. Swisher, Reza J. Mehran, Boris Sepesi, Manoop S. Bhutani, Brian Weston, Emmanuel Coronel, Rebecca Waters, Jane E. Rogers, Y Jiménez-Martínez, L. R. Lyons, Norelle R. Reilly, James C. Yao, Jaffer A. Ajani, Mariela Blum Murphy	2024	1
3	Artificial intelligence-augmented analysis of contemporary procedural, mortality, and cost trends in carcinoid heart disease in a large national cohort with a focus on the “forgotten pulmonic valve” Frontiers in Cardiovascular Medicine ·Dominique Monlezun, 王展峰, Anjuly Alvarado Grajales, F. A. Scheffier, 古川博雄, M. Asfal Huda, R. Patel, Alberto Menini, Dan Halperin, Arvind Dasari, Efstratios Koutroumpakis, Peter Kim, Juan Lopez‐Mattei, Syed Wamique Yusuf, Mehmet Çilingiroğlu, Mamas A. Mamas, Igor D. Gregorič, James C. Yao, Saamir Hassan, Cezar Iliescu	2023	2
4	Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features The Oncologist ·Hop S. Tran Cao, Russell G. Witt, Khaled M. Elsayes, D. Omirbekova, Lianchun Xiao, Thorben Alles, (unknown), (unknown), Sunyoung S. Lee, Yehia I. Mohamed, Armeen Mahvash, Ching‐Wei D. Tzeng, Yun Shin Chun, Eugene J. Koay, Asif Rashid, Manal M. Hassan, James C. Yao, Jean‐Nicolas Vauthey, Ahmed O. Kaseb	2023	0
5	Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ Nature Communications ·Yi Liu, Yasunori Deguchi, Daoyan Wei, Fuyao Liu, Micheline J. Moussalli, Farida Azizova, Donghui Li, Huamin Wang, K. Ganter, Jennifer K. Colby, Jing Wang, Xiaofeng Zheng, Haoqiang Ying, Mihai Gagea, Baoan Ji, Jiaqi Shi, James C. Yao, Xiangsheng Zuo, Imad Shureiqi	2022	45
6	Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors International Journal of Molecular Sciences ·Shivanand Pudakalakatti, Mark Titus, С. Ю. Клепикова, Hiroshi Kanatake, Niki M. Zacharias, Imad Shureiqi, Yi Liu, James C. Yao, Xiangsheng Zuo, Pratip K. Bhattacharya	2022	9
7	ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours Journal of Neuroendocrinology ·Rodney J. Hicks, Clarisse Dromain, Wouter W. de Herder, Frederico Costa, Christophe M. Deroose, Andrea Frilling, Anna Koumarianou, Eric P. Krenning, Éric Raymond, Lisa Bodei, Halfdan Sørbye, Staffan Welin, Bertram Wiedenmann, Damian Wild, James R. Howe, James C. Yao, Dermot O’Toole, Anders Sundin, Vikas Prasad	2021	13
8	Mechanisms of socioeconomic differences in COVID-19 screening and hospitalizations PLoS ONE ·Jarrod E. Dalton, Douglas Gunzler, Vardhmaan Jain, Adam T. Perzynski, Neal V. Dawson, Douglas Einstadter, Yasir Tarabichi, Peter B. Imrey, Michael Lewis, Michael W. Kattan, James C. Yao, Glen B. Taksler, Kristen A. Berg, Pearly Lim, David C. Kaelber, Lara Jehi, Ankur Kalra	2021	8
9	<p>Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study</p> OncoTargets and Therapy ·James C. Yao, Do‐Youn Oh, Jiaming Qian, Young Suk Park, 西岡弘雅, Antonia Ridolfi, Miguel Izquierdo, Tetsuhide Ito, Liqun Jia, Izumi Komoto, Virote Sriuranpong, Yasuhiro Shimada	2019	5
10	Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study Scientific Reports ·Chan Shen, Arvind Dasari, Ying Xu, Shouhao Zhou, Nanik Indah Setianingsih, Ripan Reftiana Rohman, Daniel M. Halperin, Ya‐Chen Tina Shih, James C. Yao	2018	13
11	Underreporting of Research Biopsies from Clinical Trials in Oncology Clinical Cancer Research ·Christine M. Parseghian, Kanwal Raghav, Robert A. Wolff, Joe Ensor, James C. Yao, Lee M. Ellis, Alda L. Tam, Michael J. Overman	2017	14
12	Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement Clinical Cancer Research ·Chad Tang, Steven I. Sherman, L. A. Cherezova, Jun Weng, Suzanne E. Davis, David S. Hong, James C. Yao, Aman U. Buzdar, George Wilding, J. Jack Lee	2017	27
13	Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study Journal of Clinical Oncology ·James C. Yao, Marianne Pavel, Catherine Lombard‐Bohas, Eric Van Cutsem, Maurizio Voi, Ulrike Brandt, Wei He, David Chen, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Timothy J. Hobday, Rodney F. Pommier, Kjell Öberg	2016	192
14	Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed? Clinical Cancer Research ·James C. Yao, Funda Meric‐Bernstam, J. Jack Lee, Sabine Eckhardt	2013	8
15	PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors Clinical Cancer Research ·Funda Meric‐Bernstam, Argun Akçakanat, Huiqin Chen, Kim‐Anh Do, Takafumi Sangai, Farrell Adkins, Ana M. González-Angulo, Asif Rashid, Katherine Crosby, Mei Dong, Alexandria T. Phan, Robert A. Wolff, Sanjay Gupta, Gordon B. Mills, James C. Yao	2012	171
16	The FGFR4-G388R Single-Nucleotide Polymorphism Alters Pancreatic Neuroendocrine Tumor Progression and Response to mTOR Inhibition Therapy Cancer Research ·Stefano Serra, Lei Zheng, Manal M. Hassan, Alexandria T. Phan, Linda J. Woodhouse, James C. Yao, Shereen Ezzat, L. Sylvia	2012	40
17	Treatment of Pancreatic Neuroendocrine Tumors (pNET) With Everolimus: Improved Progression-Free Survival Compared With Placebo (RADIANT-3) Pancreas ·Manisha H. Shah, Kjell Öberg, Tetsuhide Ito, Catherine Lombard‐Bohas, Edward M. Wolin, Eric Van Cutsem, Carolin Sachs, Robert Winkler, Jeremie Lincy, Yuu Yaoita, James C. Yao	2011	1
18	Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity Cancer Research ·Zhiliang Jia, Yong Gao, Liwei Wang, Qiang Li, Jun Zhang, Xiangdong Le, Daoyan Wei, James C. Yao, David Chang, Suyun Huang, Keping Xie	2010	63
19	Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial Journal of Clinical Oncology ·James C. Yao, Catherine Lombard‐Bohas, Éric Baudin, Larry K. Kvols, Philippe Rougier, Philippe Ruszniewski, Sakina Hoosen, J. Peter, T Haas, David Lebwohl, Eric Van Cutsem, Matthew H. Kulke, Timothy J. Hobday, Thomas M. O’Dorisio, Manisha H. Shah, Guillaume Cadiot, Gabriele Luppi, James Posey, Bertram Wiedenmann Hit paper breakdown →	2009	487
20	Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer Clinical Cancer Research ·Guanzhen Yu, Jiejun Wang, Ying Chen, Xi Wang, Jun Pan, Gang Li, Zhiliang Jia, Qiang Li, James C. Yao, Keping Xie	2009	135

About James C. Yao

James C. Yao is a scholar working on Neurology, Oncology, Epidemiology, Hepatology and Gastroenterology, having authored 326 papers that have together received 23.0k indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (195 papers), Lung Cancer Research Studies (154 papers), Neuroblastoma Research and Treatments (133 papers), Gastric Cancer Management and Outcomes (40 papers), Pancreatic and Hepatic Oncology Research (32 papers), PI3K/AKT/mTOR signaling in cancer (21 papers), Colorectal Cancer Treatments and Studies (18 papers) and Hepatocellular Carcinoma Treatment and Prognosis (17 papers). The work is most often cited by research in Neurology (11.4k citations), Oncology (16.9k citations), Epidemiology (16.9k citations), Gastroenterology (1.1k citations) and Pulmonary and Respiratory Medicine (2.7k citations). James C. Yao has collaborated with scholars based in United States, Switzerland and France. Frequent co-authors include Alexandria T. Phan, Asif Rashid, Douglas B. Evans, Manal M. Hassan, Jaffer A. Ajani, Colleen Leary, Arvind Dasari, Daniel M. Halperin, Cecile G. Dagohoy and Jeannette E. Mares. Their work appears in journals such as Journal of Clinical Oncology, Pancreas, Annals of Oncology, Clinical Cancer Research and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact